ViiV's HIV Drug Hits Endpoints in Late-Stage Comparison Trial

GlaxoSmithKline’s ViiV Healthcare said HIV patients who switched to Dovato (dolutegravir plus lamivudine) had similar success in maintaining viral suppression for at least six months as patients on a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs.